Navigation Links
Third-party blood stem cell transplantation as a factor to impact on poor graft function
Date:3/18/2013

Putnam Valley, NY. (March 18, 2013) When a research team in China evaluated the efficacy and safety of using mesenchymal stem cells (MSCs) expanded from the bone marrow of non-self-donors to treat patients experiencing poor graft function (PGF) after receiving transplants of non-self-donated blood stem cells (allo-HSCT), they found that the mesenchymal stem cells were both safe and effective for treating primary and secondary PGF.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0832liu.

"Allogenic hematopoietic stem cell transplantation can cure many hematologic diseases," said study co-author Dr. Qifa Liu of the Southern Medical University in Guangzhou, China. "However, poor graft function is a complication that occurs in five to 27 percent of patients receiving allo-HSCT and is associated with considerable morbidity and mortality."

According to the researchers, graft function may be poor after allogenic hematopoietic stem cell transplantation because of slow or incomplete reconstitution of blood counts or decreasing blood counts. PGF, which is poorly understood, is a potentially life-threating condition when it leads to graft vs. host disease (GVHD).

In this study, when 20 patients demonstrated risk factors for PGF, researchers infused them with MSCs derived from bone marrow from third-party donors. PGF had developed in five patients with acute GVHD and two patients had chronic GVHD.

"The patients receiving the MSCs achieved either complete responses or improved GVHD," said the researchers. "However, the PGF did not improve when immunosuppressive agents were given. This means that additional studies will be needed to determine whether PGF is associated with immunologic factors."

One unanswered question, said the researchers, was whether the immunosuppressive properties of MSCs are an important factor that could have a favorable impact on potential problems such as an increased risk of infection or tumor relapse following cell transplantation.

"Although six of 20 patients died from infections within the first 100 days of MSC transplantation, we could not safely conclude that MSCs increased the incidence of infections other than Epstein-Barr," they wrote.

In conclusion, the researchers noted that "clinical applications of human MSCs are evolving rapidly with goals of improving hematopoietic engraftment and preventing GVHD after allogenic hematopoietic stem cell transplantation."

"This study highlights the potential impact of allogeneic mesenchymal stem cell transplants as an adjunctive therapy for hematopoietic stem cell transplantation to reduce the likelihood of the patient developing graft versus host disease after exhibiting risk factors for poor functioning of the grafted cells" said Dr. Paul R. Sanberg, distinguished professor at the Center of Excellence for Aging and Brain Repair, University of South Florida.
'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. White blood cells found to play key role in controlling red blood cell levels
2. Prenatal exposure to pesticide DDT linked to adult high blood pressure
3. Temp-controlled nanopores may allow detailed blood analysis
4. Omega-3s from fish vs. fish oil pills better at maintaining blood pressure in mouse model
5. Stressed proteins can cause blood clots for hours
6. Study uncovers enzymes double life, critical role in cancer blood supply
7. Manchester patients take part in pioneering heart attack blood test trial
8. Blood vessels sniff gut microbes to regulate blood pressure
9. Childhood blood lead levels rise and fall with exposure to airborne dust in urban areas
10. Blood is thicker than water -- and blood plasma is, too
11. Rice University lab show how blood vessels regroup after stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 ... growing at a compound annual growth rate (CAGR) of 24.0% ... global markets for synthetic biology. - Analyses of global market ... of compound annual growth rates (CAGRs) through 2021. - Coverage ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017 Aviva Systems ... announced the acquisition of GenWay Biotech Incorporated, a ... service and product offering for both the research ... facilitate growth and enhance capabilities for both entities. GenWay,s ... ELISA assays will nicely complement ASB,s objective to ...
(Date:2/22/2017)... Santa Clara, CA (PRWEB) , ... February 22, 2017 , ... ... is hosting a free AFM Luncheon for all SPIE attendees ... San Jose, CA, just one block from the San Jose Convention Center. The ...
(Date:2/22/2017)... ... 22, 2017 , ... LabRoots , the leading provider ... world, is pleased to announce the 2nd annual Precision Medicine Virtual Conference. The ... conference focused on the development and advancements in precision medicine. , Precision Medicine ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Daniel Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH Division ... Evaluation Staff has joined the company as an Expert Consultant. , In Dr. ...
Breaking Biology Technology: